Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The range of therapeutic treatment options for central nervous system (CNS) diseases is greatly limited by the blood‐brain barrier (BBB). While a variety of strategies to circumvent the blood‐brain barrier for drug delivery have been investigated, little clinical success has been achieved. Focused ultrasound (FUS) is a unique approach whereby the transcranial application of acoustic energy to targeted brain areas causes a noninvasive, safe, transient, and targeted opening of the BBB, providing an avenue for the delivery of therapeutic agents from the systemic circulation into the brain. There is a great need for viable treatment strategies for CNS diseases, and we believe that the preclinical success of this technique should encourage a rapid movement towards clinical testing. In this review, we address the versatile applications of FUS‐mediated BBB opening, the safety profile of the technique, and the physical and biological mechanisms that drive this process. This article is part of the Special Issue entitled “Beyond small molecules for neurological disorders”. HighlightsFocused ultrasound allows noninvasive targeted opening of the blood–brain barrier.A variety of therapeutics have been delivered with positive functional outcomes.Safety profile is high when appropriate ultrasound parameters are used.Clinical trials using focused ultrasound to deliver drugs are underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Other neurodegenerative disorders in which BBB dysfunction has been observed include Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) (Zlokovic, 2008).”
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798 · cited 7×
“Together, these bonds create a tight link between ECs, contributing to a ‘physical barrier’which limits paracellular diffusion to small ( 400e500 Da), water soluble molecules (Pardridge, 2005).”
InfluentialThe blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“While immunotherapy has shown promise in reducing amyloid beta (Ab) in mouse models of AD (Bard et al., 2000; Wilcock et al., 2004), the low levels anti-Ab antibodies that enter the CNS from the bloodstream may hinder the efficiency of this treatment avenue (Banks et al., 2002).”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“Intravenous injection of adeno-associated virus-9 (AAV9) has been shown to target various cell populations of the CNSwithout BBBO (Foust et al., 2009).”
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 1×
“In mice, this protein variant triggers an inflammatory response in pericytes, which is thought to cause chronic BBB dysfunction and contribute to neurodegenerative changes (Bell et al., 2012).”
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278 · cited 1×
“It is also possible to tag drugs with various molecular groups to inhibit endogenous efflux pumps (Batrakova and Kabanov, 2008), or to take advantage of innate biological processes, such as receptor-mediated transcytosis (Pardridge, 2005) and cell-mediated transport mechanisms (Jain et al., 2003).”
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Scharfman, H., Goodman, J., Macleod, A., Phani, S., Antonelli, C., & Croll, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.016 · Cited by 719
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy
Liang, S., Deng, X., Ma, P., Cheng, Z., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202003214 · Cited by 598
Activating Drugs with Sound: Mechanisms Behind Sonodynamic Therapy and the Role of Nanomedicine
Choi, V., Rajora, M. A., & Zheng, G. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00029 · Cited by 237
Metadata
- Authors
- Poon, C., McMahon, D., & Hynynen, K.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 120
- Pages
- 20-37
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2278168926
- Cited by
- 148
- References
- 23
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. https://app.cochat.ai/papers/10.1016/j.neuropharm.2016.02.014
- The paper
- Poon, C., McMahon, D., & Hynynen, K. (2017). Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2016.02.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.